Amyloidosis is not cancer. It is a group of diseases caused by misfolded proteins that build up in organs and tissues, gradually interfering with normal function. However, the most common form of systemic amyloidosis is closely linked to the same type of abnormal cells that cause certain blood cancers, which is why the two are often confused and why some amyloidosis patients receive chemotherapy.
Why Amyloidosis Gets Confused With Cancer
Cancer is defined by uncontrolled cell growth. Amyloidosis is defined by protein buildup. In cancer, rogue cells multiply and invade healthy tissue. In amyloidosis, proteins fold into an abnormal shape, clump together into stiff fibers called amyloid fibrils, and deposit in organs like the heart, kidneys, liver, or nerves. The damage comes from these protein deposits, not from a growing mass of cells.
The confusion exists for a good reason, though. The most commonly diagnosed systemic form, called AL amyloidosis, is caused by defective plasma cells in the bone marrow. These are the same type of cells involved in multiple myeloma, a blood cancer. In AL amyloidosis, the plasma cells produce abnormal protein fragments (light chains) that misfold and accumulate in organs. The key difference is the scale of the cell problem: AL amyloidosis patients typically have a low burden of abnormal plasma cells, with a median of about 7% to 10% in the bone marrow. Patients without a concurrent myeloma diagnosis have less than a 1% chance of ever progressing to overt myeloma.
So while AL amyloidosis shares a biological root with blood cancer, the disease itself is driven by toxic protein deposits rather than tumor growth.
The Major Types of Amyloidosis
There are several forms of amyloidosis, and most have nothing to do with cancer at all.
- AL amyloidosis (primary): Caused by abnormal plasma cells in the bone marrow producing misfolded light chain proteins. This is the type most closely linked to blood cancers. It can affect virtually any organ, including the heart, kidneys, liver, and nerves. An enlarged tongue (macroglossia) is one of its more distinctive signs.
- ATTR amyloidosis: Caused by a protein called transthyretin that becomes unstable and forms amyloid fibrils. A hereditary version results from a gene mutation; a “wild-type” version occurs without any mutation and typically causes heart problems in older men. Neither form involves cancer.
- AA amyloidosis (secondary): Triggered by chronic infections or inflammatory diseases like rheumatoid arthritis. The liver produces high levels of an inflammatory protein, part of which deposits as amyloid. It usually affects the kidneys first. No cancer connection.
AL amyloidosis has an estimated annual incidence of about 10 cases per million people worldwide, making it rare. ATTR amyloidosis, particularly the wild-type form, is increasingly recognized as more common than previously thought, especially among older adults with unexplained heart failure.
Why Chemotherapy Is Used for a Non-Cancer Disease
This is the detail that understandably confuses people. If AL amyloidosis isn’t cancer, why do patients receive chemotherapy and even stem cell transplants?
The answer is practical: the source of the toxic proteins is a clone of abnormal plasma cells, and the fastest way to stop organ damage is to eliminate those cells. The abnormal plasma cells in AL amyloidosis are CD38-positive, just like myeloma cells, so treatments originally developed for myeloma work against them. Combination regimens that include a targeted antibody can induce rapid responses by wiping out the amyloid-producing cell clones. Stem cell transplants offer deeper, more durable suppression of the harmful protein production. The goal of treatment isn’t to shrink a tumor. It’s to shut down the factory making the damaging proteins so that organs have a chance to recover.
Symptoms That Bring People to a Diagnosis
Amyloidosis is notoriously difficult to catch early because its symptoms mimic many other conditions. What shows up depends on which organs are affected.
Heart involvement occurs in up to 50% of AL amyloidosis patients. The amyloid deposits stiffen the heart muscle, leading to heart failure symptoms like shortness of breath, fatigue, and swelling in the legs. Symptomatic heart failure at diagnosis carries a particularly poor outlook. Kidney involvement often shows up as protein spilling into the urine or declining kidney function. Nerve damage can cause numbness, tingling, or pain in the hands and feet. Bruising around the eyes (periorbital purpura) is one of the more recognizable physical signs and results from amyloid weakening small blood vessels.
Because these symptoms overlap with so many other diseases, diagnosis is often delayed. Longer time from first symptoms to diagnosis is independently associated with a higher risk of death.
How Amyloidosis Is Diagnosed
A definitive diagnosis requires a tissue biopsy. A sample is stained with a dye called Congo red, which turns amyloid deposits salmon-pink under normal light. Under polarized light, the deposits glow apple-green, a finding considered definitive for amyloid. Once amyloid is confirmed, identifying the specific type of protein is critical because treatment differs dramatically depending on whether it’s AL, ATTR, or another form. Newer techniques using mass spectrometry can analyze the protein composition of amyloid deposits with high precision.
Survival and Outlook
For AL amyloidosis, outcomes have improved substantially over the past few decades. Median survival has risen from about 1.4 years for patients diagnosed before 1990 to 4.6 years for those diagnosed between 2010 and 2019. Early death within six months of diagnosis has dropped from 23% to 13%. More than one in five patients now survive at least 10 years after diagnosis, and among those who receive intensive treatment with stem cell transplants, roughly 30% reach 15 to 20 years of survival.
Heart involvement remains the most important factor in prognosis. Cardiac failure and sudden unexpected death together account for over half of disease-related deaths. Age matters too: patients diagnosed at 70 or older have seen only marginal improvements in survival compared to younger patients. Early diagnosis, before significant organ damage accumulates, consistently offers the best chance of a good outcome.
Treatment for Non-Cancer Forms
ATTR amyloidosis has its own treatment landscape, entirely separate from chemotherapy. Two approaches have emerged: stabilizers that prevent the transthyretin protein from breaking apart into amyloid-forming fragments, and gene silencers that reduce the liver’s production of the protein in the first place. Both oral stabilizers and injectable gene-silencing therapies have shown significant reductions in disease progression, heart failure complications, and death compared to placebo in clinical trials. One gene-silencing therapy is given as an injection just once every three months. These treatments have transformed ATTR from a condition with no effective therapy into one with multiple proven options.
AA amyloidosis is managed primarily by controlling the underlying infection or inflammatory disease that drives it. When the source of inflammation is brought under control, amyloid deposits can sometimes stabilize or even gradually clear.